Genkyotex: Disclosure of the Total Number of Voting Rights & Shares Pursuant to Article L. 233-8 II of the French Commercial ...
05 Ottobre 2020 - 5:45PM
Business Wire
(AMF – Autorité des Marchés
Financiers)
Regulatory News:
Genkyotex (Paris:GKTX) (Brussels:GKTX):
Genkyotex shares
ISIN code FR00011790542 –
Euronext Paris & Brussels
Date
Number of shares making up the
share capital
Number of voting
rights
September 30, 2020
11,548,562
Theoretical number of voting
rights(1): 11,548,562
Number of voting rights
exercisable at a shareholders’ meeting(2): 11,541,930
(1) In accordance with Article 223-111 of the AMF’s General
Regulation, this number of shares is calculated based on all shares
carrying the right to vote, including those stripped of voting
rights. (2) Less shares stripped of voting rights.
About Genkyotex Genkyotex is the leading
biopharmaceutical company in NOX therapies, listed on the Euronext
Paris and Euronext Brussels markets. Its unique platform enables
the identification of orally available small-molecules which
selectively inhibit specific NOX enzymes that amplify multiple
disease processes such as fibrosis, inflammation, pain processing,
cancer development, and neurodegeneration. Genkyotex is developing
a pipeline of first-in-class product candidates targeting one or
multiple NOX enzymes. The lead product candidate, setanaxib
(GKT831), a NOX1 and NOX4 inhibitor has shown evidence of
anti-fibrotic activity in a Phase II clinical trial in primary
biliary cholangitis (PBC, a fibrotic orphan disease). Based on its
positive Phase II results, a phase 3 trial with setanaxib in PBC is
being planned. Setanaxib is also being evaluated in an
investigator-initiated Phase II clinical trial in Type 1 Diabetes
and Kidney Disease (DKD). A grant from the United States National
Institutes of Health (NIH) of $8.9 million was awarded to Professor
Victor Thannickal at the University of Alabama at Birmingham (UAB)
to fund a multi-year research program evaluating the role of NOX
enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung
disease that results in fibrosis of the lungs. The core component
of this program is a Phase 2 trial with setanaxib in patients with
IPF scheduled to recruit patients in first semester of 2020. This
product candidate may also be active in other fibrotic indications.
Genkyotex also has a versatile platform well-suited to the
development of various immunotherapies (Vaxiclase). A partnership
covering the use of Vaxiclase as an antigen per se (GTL003) has
been established with Serum Institute of India Private Ltd (Serum
Institute), the world’s largest producer of vaccine doses, for the
development by Serum Institute of cellular multivalent combination
vaccines against a variety of infectious diseases
For further information, please go to www.genkyotex.com
or investors@genkyotex.com
Disclaimer This press
release may contain forward-looking statements by the company with
respect to its objectives. Such statements are based upon the
current beliefs, estimates and expectations of Genkyotex’s
management and are subject to risks and uncertainties such as the
company's ability to implement its chosen strategy, customer market
trends, changes in technologies and in the company's competitive
environment, changes in regulations, clinical or industrial risks
and all risks linked to the company's growth. These factors as well
as other risks and uncertainties may prevent the company from
achieving the objectives outlined in the press release and actual
results may differ from those set forth in the forward-looking
statements, due to various factors. Without being exhaustive, such
factors include uncertainties involved in the development of
Genkyotex’s products, which may not succeed, or in the delivery of
Genkyotex’s products marketing authorizations by the relevant
regulatory authorities and, in general, any factor that could
affects Genkyotex’s capacity to commercialize the products it
develops. No guarantee is given on forward-looking statements which
are subject to a number of risks, notably those described in the
universal registration document filed with the AMF on April 30,
2020 under number 20-0434, and those linked to changes in economic
conditions, the financial markets, or the markets on which
Genkyotex is present. Genkyotex products are currently used for
clinical trials only and are not otherwise available for
distribution or sale
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201005005614/en/
Genkyotex